Ipamorelin

Ipamorelin is a synthetic pentapeptide and one of the most selective growth hormone secretagogues ever developed. It belongs to the GHRP family, but is distinguished in the literature by how cleanly it acts — stimulating growth-hormone release with little of the off-target hormonal noise associated with earlier compounds in its class.

What you’re reading about

Ipamorelin is often described simply as a “GHRP” (growth hormone releasing peptide). Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — just five amino acids, which is part of why it is such a tractable research tool.

Mechanism under investigation

Ipamorelin acts as an agonist at the ghrelin receptor (GHS-R1a), the same receptor the body’s own hunger-and-growth signal uses. Binding there triggers release of growth hormone from the pituitary. What made Ipamorelin notable in the original research is its selectivity: unlike earlier secretagogues, it produces minimal elevation of cortisol, prolactin, or ACTH, giving researchers a cleaner way to isolate GH signaling from stress-hormone effects.

Research applications

• Selective stimulation of pulsatile growth-hormone release.
• Gastrointestinal motility research — ghrelin-receptor agonism affects gut transit.
• Body composition, lean tissue, and recovery endpoints in animal models.
• Bone-density and connective-tissue markers mediated by the GH/IGF-1 axis.

Clinical outlook

Ipamorelin has genuinely reached human research. Two completed Phase 2 trials investigated it in a direction that may surprise people who know it only as a GH peptide: post-operative ileus — the temporary shutdown of gut motility after abdominal surgery (NCT00672074, NCT01280344). That work followed from its ghrelin-receptor activity rather than its growth-hormone effect. Researchers continue to study both arms of its biology: the GH-secretagogue pathway for body composition and recovery, and the motility pathway for gastrointestinal medicine.